Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Molecular Diagnostics: Page 3
Matrix Medical Network sells laboratory service line to Karrington Clinical Laboratory
The transition of ownership is part of an overall strategy Matrix announced last year to refocus its portfolio of services on in-home health and care assessments.
January 4, 2023
FoundationOne Liquid CDx receives FDA approval for use with Rozlytrek (entrectinib)
The CDx is indicated for use with patients who do not have a tissue sample available and may be appropriate for treatment with Rozlytrek (entrectinib), a targeted therapy developed by Genentech.
January 4, 2023
Aptorum Group announces publication on metagenomics sequencing workflow on Illumina platforms
The paper, entitled “Towards a rapid-turnaround low-depth unbiased metagenomics sequencing workflow on the Illumina platforms,” is available as a preprint on medRxiv.
January 4, 2023
Datar Cancer Genetics obtains FDA breakthrough device designation for blood test to detect inaccessible brain tumors
A prospective, blinded study by London’s Imperial College researchers showed the TriNetra-Glio liquid biopsy test, which requires 15 mL of blood, can detect malignant brain tumors.
January 3, 2023
Burning Rock nabs FDA breakthrough device designation for multicancer detection blood test
The test, called OverC MCDBT, is intended for early detection of esophageal, liver, lung, ovarian, and pancreatic cancers in adults of either sex from 50 to 75 years of age and at average risk for cancer.
January 3, 2023
Discovery of destructive CRISPR enzyme opens up diagnostic, therapeutic applications for molecular scissors
In a pair of Nature papers, researchers describe the structure and function of Cas12a2, which binds and cuts target DNA to shut off a specific gene so that the enzymes can be used as molecular scissors.
January 4, 2023
Most Popular
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
Roche reports flat diagnostics revenue growth for 2022
French point-of-care testing firm Biosynex to acquire Chembio Diagnostics for $17.2M
OIG report outlines challenges with CDC-supported COVID-19 vaccination programs
Alercell preparing January launch of sequencing test for leukemia
The Montana-based firm also aims to launch a methylation-based molecular diagnostic test for lung cancer later in the first quarter of 2023.
December 29, 2022
Natera supports guideline proposing donor-derived cfDNA testing for heart transplant surveillance
The International Society for Heart and Lung Transplantation proposes monitoring for rejection with noninvasive biomarkers or biopsy monthly during the first six months post-transplant, as well as testing in the ninth and 12th months post-transplant.
December 23, 2022
Menarini study demonstrates impact of circulating tumor cell counting on metastatic breast cancer survival
The data demonstrated that a single assessment of circulating tumor cell count by CellSearch before treatment commences may lead to increased overall survival in patients with metastatic breast cancer.
December 22, 2022
BlueStar Genomics announces rebranding as ClearNote Health, commercialization of pancreatic cancer test
The DNA-based blood test is already available in the U.S. through the ClearNote Health physician experience program.
December 22, 2022
Foundation Medicine obtains FDA approval for NSCLC CDx
The blood-based test’s first group approval improves physicians’ ability to identify patients in this population for treatment with certain FDA-approved tyrosine kinase inhibitors, Foundation Medicine said.
December 21, 2022
Medicare policy increases access to noninvasive colorectal cancer tests: Exact Sciences
CMS is expanding coverage for certain colorectal cancer screening tests by reducing the minimum age payment and coverage limitation from 50 to 45 years.
December 20, 2022
Previous Page
Page 3 of 170
Next Page
